This innovative medical technology for acute myocardial infarction (AMI) leverages two inventions: a light-activated nitric oxide (NO) nanomedicine and an optofluidic catheter. The catheter delivers light and nanomedicine, enabling localized and rapid NO generation near the infarction zone. We demonstrated treatment efficacy on a pig AMI model, showing significantly reduced myocardial necrosis and apoptosis, and improved ventricular function.

This innovative myocardial infarction (MI) medical technology combines a nanomedi-cine and an optical microfluidic cardiac catheter. It has demonstrated, for the first time, the local and rapid generation of nitric oxide. Animal experiments conducted in a pig MI model have shown a reduction in myocardial necrosis and apoptosis, along with significant improvement in left ventricular contractile function, post-infarction.

Our technology, combining an optofluidic catheter with light-activated nanomedicine, enhances acute myocardial infarction (AMI) treatment by improving efficacy and reducing costs. It also enables the development of compatible medical devices and advanced drug delivery systems, extending drug lifespans and fostering new patents. Additionally, this technology can be applied to cancer and chronic inflammatory disease treatments, offering significant clinical and economic benefits.